Please login to the form below

Not currently logged in
Email:
Password:

Relay Therapeutics appoints Sarah O’Brien as VP of HR

She joins the biotech from Sobi

Sarah O'BrienRelay Therapeutics, a biotech based in the US, has appointed its new vice president of human resources in the form of Sarah O’Brien.

She joins the biotech from Sobi in North America, where she was responsible for a variety of global initiatives across learning, development and culture.

O’Brien said: “I am thrilled to join this exceptional team that has a strong culture and compelling scientific approach.

“I am passionate about supporting growth and development at Relay so that we can create medicines wit meaningful clinical impact.”

Prior to Sobi, O’Brien spent seven years working at Novartis for its vaccines arm and then with the Novartis Institute for Biomedical Research (NIBR), where she worked closely with the translational medicines, oncology and immunotherapy organisations.

Sanjiv Patel, president and chief executive officer, Relay Therapeutics, said: “Sarah brings with her valuable insights that can be applied to continue advancing our commitment to advancing drug discovery and developing our team.

“We look forward to her working across the organisation to guide Relay’s growth while ensuring that we retain our strong commitment to both our people and culture, and remain true to our core values.”

5th December 2017

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mind+Matter

We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics